ICRC-WEYER Ready for Increased Demand in Advanced Therapy Trials

Press Release – ICRC-WEYER GmbH
ICRC-WEYER Ready for Increased Demand in Advanced Therapy Trials

ICRC Weyer Logo

Contact Supplier: ICRC-WEYER GmbH
Supplier Press Release: ICRC-WEYER Ready for Increased Demand in Advanced Therapy Trials
Address: Boelschestrasse 2, D-12587 Berlin, Germany
Tel: +49 (30) 40 39 37 – 0
Fax: +49 (30) 40 39 37 – 18
Website: www.icrc-weyer.com


NOVEMBER 16, 2012

ICRC-WEYER Ready for Increased Demand in Advanced Therapy Trials

Contract Research Organisation, ICRC-Weyer GmbH has recently taken part in a hugely informative and successful meeting with several other biotech companies and service providers from the UK and Germany. Hosted by NanoKTN biotechnology and held at the British Embassy in Berlin in September 2012, ICRC-Weyer was represented by two members of the team. Presentations at the event were centred on the field of regenerative medicine and allowed the open discussion of potential collaborations.

Those attending the event believe that the area of regenerative medicine is in a phase of rapid development. One of the attendees, ICRC-Weyer’s, Head of Medical Writing & Scientific Consulting, Dr. Iris Hardewig said: “Due to new regulations in the field of Advanced Therapy Medicinal Products (ATMP) a wave of registrations for such can be expected in the coming 10 to 15 years. Hence, the number of clinical trials for these products will increase significantly. As a medium-sized CRO providing specialized and flexible services to small biotech companies, ICRC-Weyer can deliver high-quality results for ATMP trials and contribute to this promising development.”

In response to the confidence and growth in the regenerative medicine market, ICRC-Weyer has taken the pre-emptive step to extend its clinical monitoring services portfolio to monitoring for trials in the area of stem cell research. This move ensures that they are perfectly placed to being able to meet the demands of the global pharmaceutical industry.

“The engaged discussions of our team members with different participating companies show that there is a lively interest in high quality clinical services in the area of regenerative medicine”, Dr. Hardewig continues, “one reason being the initiation of the 7th Framework Programme (FP7) by the EU which provides an important source for funding early clinical development of advanced therapies. The program has paved the way for further research in Europe in the area of ATMP.”

About the NanoKTN Event
The networking event was hosted by UK Nanotechnology Knowledge Transfer Network (NanoKTN) and BioTOP Berlin-Brandenburg. The meeting is designed to bring a selection of the UK’s leading companies and academics developing nano-structured materials and biomaterials for use in tissue engineering and regenerative medicine, to meet with centres of research excellence in Berlin.

About FP7
The Seventh Framework Programme for Research and Technological Development (FP7) is the EU’s main instrument for funding research in Europe. The program supports research in selected priority areas – the aim being to make, or keep, the EU as a world leader in those sectors.

About ICRC-Weyer
ICRC-Weyer is an established all-phase contract research organization (CRO) based in Berlin, Germany. The company was founded in 1993 by Prof. Dr. Geerd Weyer and offers services ranging from pre-clinical through to phase IV clinical trials. ICRC-Weyer provides complete turnkey solutions including data management, monitoring and medical review services for all stages of the clinical development process. ICRC-Weyer has special expertise in Advanced Therapies, Nutrition, CDISC Data Standards and Medical Review.

Contact:
ICRC-Weyer GmbH
Johann Daniel Weyer
Tel: +49 30 403937-0
Email: daniel.weyer@icrc-weyer.com

For more information or to discuss ICRC-WEYER ready for increased demand in advanced therapy trials please contact us directly.

Comments are closed.